Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival
Open Access
- 4 November 2022
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Abstract
Molecular heterogeneity is a key feature of glioblastoma that impedes patient stratification and leads to large discrepancies in mean patient survival. Here, we analyze a cohort of 96 glioblastoma patients with survival ranging from a few months to over 4 years. 46 tumors are analyzed by mass spectrometry-based spatially-resolved proteomics guided by mass spectrometry imaging. Integration of protein expression and clinical information highlights three molecular groups associated with immune, neurogenesis, and tumorigenesis signatures with high intra-tumoral heterogeneity. Furthermore, a set of proteins originating from reference and alternative ORFs is found to be statistically significant based on patient survival times. Among these proteins, a 5-protein signature is associated with survival. The expression of these 5 proteins is validated by immunofluorescence on an additional cohort of 50 patients. Overall, our work characterizes distinct molecular regions within glioblastoma tissues based on protein expression, which may help guide glioblastoma prognosis and improve current glioblastoma classification.Keywords
All Related Versions
This publication has 78 references indexed in Scilit:
- Direct Detection of Alternative Open Reading Frames Translation Products in Human Significantly Expands the ProteomePLOS ONE, 2013
- Proteomics of gliomas: Initial biomarker discovery and evolution of technologyNeuro-Oncology, 2011
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- In Vivo, In Situ Tissue Analysis Using Rapid Evaporative Ionization Mass SpectrometryAngewandte Chemie International Edition, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based TherapeuticsClinical Cancer Research, 2007
- Solid Ionic Matrixes for Direct Tissue Analysis and MALDI ImagingAnalytical Chemistry, 2006
- Positive and Negative Associations of Human Leukocyte Antigen Variants with the Onset and Prognosis of Adult Glioblastoma MultiformeCancer Epidemiology, Biomarkers & Prevention, 2005